RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

Systems & Services

 

Issue 44
A minimum acceptable standard of care for every patient
Issue 42
Cutting unnecessary deaths from cervical cancer
Issue 41
An advanced oncology degree for busy specialists across the globe
Issue 36
Should you respect a dying wish?
Issue 31
EUROCARE 4 delivers its verdict
Issue 30
Why are cancer patients still suffering unnecessary pain?
Issue 29
Europe's rare cancer community calls for a more radical approach
Issue 27
A diet of hopes and half-truths
Issue 26
Why is cancer killing more men than women?
Issue 25
We're back!
Issue 21
The X factor
Issue 20
How cancer hit the Romanina political agenda
Issue 17
Saving lives through changing systems and practices
Issue 9
Specialist centres: can surgeons heal the wounds?
Issue 7
A healthy diet is simply a matter of good taste
Issue 5
Cancer nurses - partners in care
Issue 3
Ireland's bumpy road to a world-class cancer service
Issue 2
Britains' cancer czar

 



 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR16 - Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists (based on a review article of Critical Reviews in Oncology Hematology)

GR182 - Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

GR183 - The current management of low-grade glioma in childhood

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.